ストックスクリーナーアプリを入手
31.34
2.15%
0.625
前日終値:
$30.72
開ける：
$30.72
24時間の取引高:
74,564
Relative Volume:
0.14
時価総額：
$1.55B
収益：
$447.57M
当期純損益:
$-38.92M
株価収益率:
-37.77
EPS:
-0.83
ネットキャッシュフロー:
$-1.15M
1週間 パフォーマンス:
-0.51%
1か月 パフォーマンス:
-0.76%
6か月 パフォーマンス:
-9.54%
1年 パフォーマンス:
+35.32%
1日の値動き範囲:
$30.70
$31.52
1週間の範囲:
$30.49
$32.44
52週間の値動き範囲:
$20.20
$43.11
Atricure Inc Stock (ATRC) Company Profile
ATRC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
31.37 | 1.56B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
517.16 | 191.65B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
173.77 | 49.57B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.39 | 42.93B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
254.27 | 37.60B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
225.27 | 15.91B | 2.90B | 467.20M | 306.90M | 6.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-17 | 再開されました | JP Morgan | Overweight |
| 2024-04-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-10-23 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-09-29 | 開始されました | UBS | Buy |
| 2021-08-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-12-18 | 繰り返されました | Needham | Buy |
| 2020-11-06 | 繰り返されました | Needham | Buy |
| 2020-04-07 | 開始されました | Oppenheimer | Outperform |
| 2020-02-06 | 開始されました | BTIG Research | Buy |
| 2020-01-24 | 繰り返されました | Needham | Buy |
| 2019-08-13 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | 開始されました | JP Morgan | Overweight |
| 2018-10-04 | 繰り返されました | Needham | Buy |
| 2018-08-02 | 繰り返されました | Needham | Buy |
| 2018-08-02 | 繰り返されました | Stifel | Buy |
| 2018-06-18 | 繰り返されました | Needham | Buy |
| 2018-04-27 | 繰り返されました | Needham | Buy |
| 2018-01-16 | 繰り返されました | Needham | Buy |
| 2017-11-02 | 繰り返されました | Needham | Buy |
| 2017-07-28 | 繰り返されました | Needham | Buy |
| 2017-05-30 | 再開されました | Piper Jaffray | Overweight |
| 2016-06-30 | 再開されました | JMP Securities | Mkt Outperform |
| 2015-10-28 | 繰り返されました | Needham | Buy |
| 2015-10-06 | 繰り返されました | Canaccord Genuity | Buy |
| 2015-10-06 | 繰り返されました | Needham | Buy |
すべてを表示
Atricure Inc (ATRC) 最新ニュース
Left Atrial Appendage Closure Devices Market Exclusive Report - openPR.com
(ATRC) On The My Stocks Page - news.stocktradersdaily.com
AtriCure Data Breach Lawsuit Investigation - Claim Depot
Artivion Inc. Data Breach Affects 5,608 in Texas - Claim Depot
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry? - simplywall.st
AtriCure to Announce Second Quarter 2025 Financial Results - The Globe and Mail
AtriCure, Inc.(NasdaqGM: ATRC) dropped from Russell 3000E Value Index - MarketScreener
AtriCure (ATRC): Leveraging Regulatory Wins and Insider Backing in a Declining Market - AInvest
Cryoablation Probe Market Size, Share | Industry Report 2030 - Grand View Research
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Yahoo Finance
Transcript : AtriCure, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
AtriCure at Goldman Sachs Conference: Strategic Growth Insights - Investing.com India
AtriCure at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com UK
AtriCure's Strategic Momentum: Leadership in Atrial Fibrillation Management Takes Center Stage - AInvest
Ameriprise Financial Inc. Invests $295,000 in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
Global Cardiac Ablation Market: Advancements in Minimally Invasive Procedures and 13% CAGR by 2030 - PharmiWeb.com
Left Atrial Appendage Closure Device Market projected to surpass US$ 8,786.032 million by 2030 at a CAGR of - EIN News
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Jane Street Group LLC - Defense World
AtriCure (NASDAQ:ATRC) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
(ATRC) Investment Analysis - news.stocktradersdaily.com
AtriCure’s chief scientific officer sells $83,600 in stock By Investing.com - Investing.com India
Insider Sell: Vinayak Doraiswamy Sells 2,500 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure’s chief scientific officer sells $83,600 in stock - Investing.com Australia
Investors push AtriCure (NASDAQ:ATRC) 3.9% lower this week, company's increasing losses might be to blame - simplywall.st
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $823,000 Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure, Inc. (ATRC) Stock Analysis: Evaluating a 52.52% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Deutsche Bank AG - Defense World
AtriCure (NASDAQ:ATRC) Upgraded by Wall Street Zen to “Buy” Rating - Defense World
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference | ATRC Stock News - GuruFocus
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance
Bank of America Corp DE Sells 208,694 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure Inc (ATRC) Trading 3.4% Higher on May 20 - GuruFocus
Focus Partners Wealth Acquires Shares of 16,306 AtriCure, Inc. (NASDAQ:ATRC) - Defense World
D. E. Shaw & Co. Inc. Sells 49,834 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure Stockholders Approve Stock Incentive Plan Amendment - TipRanks
Left Atrial Appendage Devices Market | Latest Trends, Growth, - openPR.com
AtriCure Names New COO, CFO - Medical Product Outsourcing
AtriCure Enrolls First Two Patients in DEEP Clinical Study - Medical Product Outsourcing
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect? - Yahoo Finance
Questex’s Fierce Healthcare Announces 2025 Fierce DEI Award Finalists - GlobeNewswire Inc.
When (ATRC) Moves Investors should Listen - news.stocktradersdaily.com
AtriCure Q1 2025 presentation: Revenue up 13.6%, raises full-year guidance - Investing.com
Dimensional Fund Advisors LP Purchases 136,015 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure CEO details growth trajectory toward becoming a $1B company - The Business Journals
AtriCure targets $517M-$527M revenue in 2025 with strong growth in appendage management and pain management - MSN
Left Atrial Appendage Closure Market to Set Phenomenal Growth - openPR.com
AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Call Transcript - Insider Monkey
Shareholders in AtriCure (NASDAQ:ATRC) have lost 40%, as stock drops 11% this past week - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch - simplywall.st
Needham cuts AtriCure stock target to $44, maintains buy rating By Investing.com - Investing.com Nigeria
Atricure Inc (ATRC) 財務データ
収益
当期純利益
現金流量
EPS
0.26%
大文字化:
|
ボリューム (24 時間):